The capacity of short-chain fructo-oligosaccharides to stimulate faecal bifidobacteria: a dose-response relationship study in healthy humans
Short-chain fructo-oligosaccharides (scFOS) are well-known for their bifidogenicity. In a large study comprising 200 healthy volunteers, we determined the bifidogenic properties of 7 non-digestible carbohydrates administered at a dose of 10 g/d in the diet; we analysed dose-response relationships of...
Saved in:
| Published in | Nutrition journal Vol. 5; no. 1; p. 8 |
|---|---|
| Main Authors | , , , , |
| Format | Journal Article |
| Language | English |
| Published |
England
BioMed Central Ltd
28.03.2006
BioMed Central BMC |
| Subjects | |
| Online Access | Get full text |
| ISSN | 1475-2891 1475-2891 |
| DOI | 10.1186/1475-2891-5-8 |
Cover
Loading…
| Abstract | Short-chain fructo-oligosaccharides (scFOS) are well-known for their bifidogenicity. In a large study comprising 200 healthy volunteers, we determined the bifidogenic properties of 7 non-digestible carbohydrates administered at a dose of 10 g/d in the diet; we analysed dose-response relationships of the bifidogenic substrates at doses ranging from 2.5 to 10 g/d in comparison with a placebo. The aim of this presentation is to give more details about the dose-response effects of short-chain fructo-oligosaccharides (scFOS).
Forty healthy volunteers (18 males, 22 females) eating their usual diets were randomly divided into 5 groups of 8 subjects and received scFOS at a dose of 2.5, 5.0, 7.5 and 10 g/d or a placebo for 7 d. Stools were collected before (day (d) 8) and at the end (day (d) 15) of sugar consumption, and tolerance was evaluated using a daily chart. RESULTS (M +/- SEM): Bifidobacteria counts increase was higher in scFOS than in placebo group for all doses tested [2.5 g/d (from 9.15 +/- 0.59 to 9.39 +/- 0.70; P = 0.02); 5 g/d (from 10.21 +/- 0.21 to 10.67 +/- 0.22; P = 0.03); 7.5 g/d (from 9.28 +/- 0.49 to 9.85 +/- 0.35;P = 0.01); 10 g/d (from 9.00 +/- 0.81 to 10.18 +/- 0.60; P = 0.003)]. A significant correlation between the ingested dose of scFOS and faecal bifidobacteria counts was observed at d15 (r2 = 0.307, P < 0.001). Total anaerobes increased at the dose of 10 g/d. No significant differences were found for Bacteroides, Lactobacillus, enterobacteria or pH in any group. The frequency of digestive symptoms was not different between scFOS at any of the doses tested and placebo. Bloating was significantly more intense during scFOS ingestion at doses of 2.5 and 5 g/d, but not at doses of 7.5 and 10 g/d. Excess flatus, borborygmi and abdominal pain did not differ from the placebo at any of the doses tested.
This study showed that scFOS is bifidogenic and well tolerated at doses ranging from 2.5 to 10 g/d, and that there is a dose-response relationship in healthy volunteers. |
|---|---|
| AbstractList | Short-chain fructo-oligosaccharides (scFOS) are well-known for their bifidogenicity. In a large study comprising 200 healthy volunteers, we determined the bifidogenic properties of 7 non-digestible carbohydrates administered at a dose of 10 g/d in the diet; we analysed dose-response relationships of the bifidogenic substrates at doses ranging from 2.5 to 10 g/d in comparison with a placebo. The aim of this presentation is to give more details about the dose-response effects of short-chain fructo-oligosaccharides (scFOS).BACKGROUNDShort-chain fructo-oligosaccharides (scFOS) are well-known for their bifidogenicity. In a large study comprising 200 healthy volunteers, we determined the bifidogenic properties of 7 non-digestible carbohydrates administered at a dose of 10 g/d in the diet; we analysed dose-response relationships of the bifidogenic substrates at doses ranging from 2.5 to 10 g/d in comparison with a placebo. The aim of this presentation is to give more details about the dose-response effects of short-chain fructo-oligosaccharides (scFOS).Forty healthy volunteers (18 males, 22 females) eating their usual diets were randomly divided into 5 groups of 8 subjects and received scFOS at a dose of 2.5, 5.0, 7.5 and 10 g/d or a placebo for 7 d. Stools were collected before (day (d) 8) and at the end (day (d) 15) of sugar consumption, and tolerance was evaluated using a daily chart. RESULTS (M +/- SEM): Bifidobacteria counts increase was higher in scFOS than in placebo group for all doses tested [2.5 g/d (from 9.15 +/- 0.59 to 9.39 +/- 0.70; P = 0.02); 5 g/d (from 10.21 +/- 0.21 to 10.67 +/- 0.22; P = 0.03); 7.5 g/d (from 9.28 +/- 0.49 to 9.85 +/- 0.35;P = 0.01); 10 g/d (from 9.00 +/- 0.81 to 10.18 +/- 0.60; P = 0.003)]. A significant correlation between the ingested dose of scFOS and faecal bifidobacteria counts was observed at d15 (r2 = 0.307, P < 0.001). Total anaerobes increased at the dose of 10 g/d. No significant differences were found for Bacteroides, Lactobacillus, enterobacteria or pH in any group. The frequency of digestive symptoms was not different between scFOS at any of the doses tested and placebo. Bloating was significantly more intense during scFOS ingestion at doses of 2.5 and 5 g/d, but not at doses of 7.5 and 10 g/d. Excess flatus, borborygmi and abdominal pain did not differ from the placebo at any of the doses tested.METHODSForty healthy volunteers (18 males, 22 females) eating their usual diets were randomly divided into 5 groups of 8 subjects and received scFOS at a dose of 2.5, 5.0, 7.5 and 10 g/d or a placebo for 7 d. Stools were collected before (day (d) 8) and at the end (day (d) 15) of sugar consumption, and tolerance was evaluated using a daily chart. RESULTS (M +/- SEM): Bifidobacteria counts increase was higher in scFOS than in placebo group for all doses tested [2.5 g/d (from 9.15 +/- 0.59 to 9.39 +/- 0.70; P = 0.02); 5 g/d (from 10.21 +/- 0.21 to 10.67 +/- 0.22; P = 0.03); 7.5 g/d (from 9.28 +/- 0.49 to 9.85 +/- 0.35;P = 0.01); 10 g/d (from 9.00 +/- 0.81 to 10.18 +/- 0.60; P = 0.003)]. A significant correlation between the ingested dose of scFOS and faecal bifidobacteria counts was observed at d15 (r2 = 0.307, P < 0.001). Total anaerobes increased at the dose of 10 g/d. No significant differences were found for Bacteroides, Lactobacillus, enterobacteria or pH in any group. The frequency of digestive symptoms was not different between scFOS at any of the doses tested and placebo. Bloating was significantly more intense during scFOS ingestion at doses of 2.5 and 5 g/d, but not at doses of 7.5 and 10 g/d. Excess flatus, borborygmi and abdominal pain did not differ from the placebo at any of the doses tested.This study showed that scFOS is bifidogenic and well tolerated at doses ranging from 2.5 to 10 g/d, and that there is a dose-response relationship in healthy volunteers.CONCLUSIONThis study showed that scFOS is bifidogenic and well tolerated at doses ranging from 2.5 to 10 g/d, and that there is a dose-response relationship in healthy volunteers. Background Short-chain fructo-oligosaccharides (scFOS) are well-known for their bifidogenicity. In a large study comprising 200 healthy volunteers, we determined the bifidogenic properties of 7 non-digestible carbohydrates administered at a dose of 10 g/d in the diet; we analysed dose-response relationships of the bifidogenic substrates at doses ranging from 2.5 to 10 g/d in comparison with a placebo. The aim of this presentation is to give more details about the dose-response effects of short-chain fructo-oligosaccharides (scFOS). Methods Forty healthy volunteers (18 males, 22 females) eating their usual diets were randomly divided into 5 groups of 8 subjects and received scFOS at a dose of 2.5, 5.0, 7.5 and 10 g/d or a placebo for 7 d. Stools were collected before (day (d) 8) and at the end (day (d) 15) of sugar consumption, and tolerance was evaluated using a daily chart. Results (m +/- SEM) Bifidobacteria counts increase was higher in scFOS than in placebo group for all doses tested [2.5 g/d (from 9.15 +/- 0.59 to 9.39 +/- 0.70; P = 0.02); 5 g/d (from 10.21 +/- 0.21 to 10.67 +/- 0.22; P = 0.03); 7.5 g/d (from 9.28 +/- 0.49 to 9.85 +/- 0.35; P = 0.01); 10 g/d (from 9.00 +/- 0.81 to 10.18 +/- 0.60; P = 0.003)]. A significant correlation between the ingested dose of scFOS and faecal bifidobacteria counts was observed at d15 (r super(2 )= 0.307, P < 0.001). Total anaerobes increased at the dose of 10 g/d. No significant differences were found for Bacteroides, Lactobacillus, enterobacteria or pH in any group. The frequency of digestive symptoms was not different between scFOS at any of the doses tested and placebo. Bloating was significantly more intense during scFOS ingestion at doses of 2.5 and 5 g/d, but not at doses of 7.5 and 10 g/d. Excess flatus, borborygmi and abdominal pain did not differ from the placebo at any of the doses tested. Conclusion This study showed that scFOS is bifidogenic and well tolerated at doses ranging from 2.5 to 10 g/d, and that there is a dose-response relationship in healthy volunteers. Abstract Background Short-chain fructo-oligosaccharides (scFOS) are well-known for their bifidogenicity. In a large study comprising 200 healthy volunteers, we determined the bifidogenic properties of 7 non-digestible carbohydrates administered at a dose of 10 g/d in the diet; we analysed dose-response relationships of the bifidogenic substrates at doses ranging from 2.5 to 10 g/d in comparison with a placebo. The aim of this presentation is to give more details about the dose-response effects of short-chain fructo-oligosaccharides (scFOS). Methods Forty healthy volunteers (18 males, 22 females) eating their usual diets were randomly divided into 5 groups of 8 subjects and received scFOS at a dose of 2.5, 5.0, 7.5 and 10 g/d or a placebo for 7 d. Stools were collected before (day (d) 8) and at the end (day (d) 15) of sugar consumption, and tolerance was evaluated using a daily chart. Results (m ± SEM) Bifidobacteria counts increase was higher in scFOS than in placebo group for all doses tested [2.5 g/d (from 9.15 ± 0.59 to 9.39 ± 0.70; P = 0.02); 5 g/d (from 10.21 ± 0.21 to 10.67 ± 0.22; P = 0.03); 7.5 g/d (from 9.28 ± 0.49 to 9.85 ± 0.35;P = 0.01); 10 g/d (from 9.00 ± 0.81 to 10.18 ± 0.60; P = 0.003)]. A significant correlation between the ingested dose of scFOS and faecal bifidobacteria counts was observed at d15 (r2 = 0.307, P < 0.001). Total anaerobes increased at the dose of 10 g/d. No significant differences were found for Bacteroides, Lactobacillus, enterobacteria or pH in any group. The frequency of digestive symptoms was not different between scFOS at any of the doses tested and placebo. Bloating was significantly more intense during scFOS ingestion at doses of 2.5 and 5 g/d, but not at doses of 7.5 and 10 g/d. Excess flatus, borborygmi and abdominal pain did not differ from the placebo at any of the doses tested. Conclusion This study showed that scFOS is bifidogenic and well tolerated at doses ranging from 2.5 to 10 g/d, and that there is a dose-response relationship in healthy volunteers. BACKGROUND: Short-chain fructo-oligosaccharides (scFOS) are well-known for their bifidogenicity. In a large study comprising 200 healthy volunteers, we determined the bifidogenic properties of 7 non-digestible carbohydrates administered at a dose of 10 g/d in the diet; we analysed dose-response relationships of the bifidogenic substrates at doses ranging from 2.5 to 10 g/d in comparison with a placebo. The aim of this presentation is to give more details about the dose-response effects of short-chain fructo-oligosaccharides (scFOS). METHODS: Forty healthy volunteers (18 males, 22 females) eating their usual diets were randomly divided into 5 groups of 8 subjects and received scFOS at a dose of 2.5, 5.0, 7.5 and 10 g/d or a placebo for 7 d. Stools were collected before (day (d) 8) and at the end (day (d) 15) of sugar consumption, and tolerance was evaluated using a daily chart. RESULTS (M ± SEM): Bifidobacteria counts increase was higher in scFOS than in placebo group for all doses tested [2.5 g/d (from 9.15 ± 0.59 to 9.39 ± 0.70; P = 0.02); 5 g/d (from 10.21 ± 0.21 to 10.67 ± 0.22; P = 0.03); 7.5 g/d (from 9.28 ± 0.49 to 9.85 ± 0.35;P = 0.01); 10 g/d (from 9.00 ± 0.81 to 10.18 ± 0.60; P = 0.003)]. A significant correlation between the ingested dose of scFOS and faecal bifidobacteria counts was observed at d15 (r2 = 0.307, P < 0.001). Total anaerobes increased at the dose of 10 g/d. No significant differences were found for Bacteroides, Lactobacillus, enterobacteria or pH in any group. The frequency of digestive symptoms was not different between scFOS at any of the doses tested and placebo. Bloating was significantly more intense during scFOS ingestion at doses of 2.5 and 5 g/d, but not at doses of 7.5 and 10 g/d. Excess flatus, borborygmi and abdominal pain did not differ from the placebo at any of the doses tested. CONCLUSION: This study showed that scFOS is bifidogenic and well tolerated at doses ranging from 2.5 to 10 g/d, and that there is a dose-response relationship in healthy volunteers. Short-chain fructo-oligosaccharides (scFOS) are well-known for their bifidogenicity. In a large study comprising 200 healthy volunteers, we determined the bifidogenic properties of 7 non-digestible carbohydrates administered at a dose of 10 g/d in the diet; we analysed dose-response relationships of the bifidogenic substrates at doses ranging from 2.5 to 10 g/d in comparison with a placebo. The aim of this presentation is to give more details about the dose-response effects of short-chain fructo-oligosaccharides (scFOS). Forty healthy volunteers (18 males, 22 females) eating their usual diets were randomly divided into 5 groups of 8 subjects and received scFOS at a dose of 2.5, 5.0, 7.5 and 10 g/d or a placebo for 7 d. Stools were collected before (day (d) 8) and at the end (day (d) 15) of sugar consumption, and tolerance was evaluated using a daily chart. RESULTS (M +/- SEM): Bifidobacteria counts increase was higher in scFOS than in placebo group for all doses tested [2.5 g/d (from 9.15 +/- 0.59 to 9.39 +/- 0.70; P = 0.02); 5 g/d (from 10.21 +/- 0.21 to 10.67 +/- 0.22; P = 0.03); 7.5 g/d (from 9.28 +/- 0.49 to 9.85 +/- 0.35;P = 0.01); 10 g/d (from 9.00 +/- 0.81 to 10.18 +/- 0.60; P = 0.003)]. A significant correlation between the ingested dose of scFOS and faecal bifidobacteria counts was observed at d15 (r2 = 0.307, P < 0.001). Total anaerobes increased at the dose of 10 g/d. No significant differences were found for Bacteroides, Lactobacillus, enterobacteria or pH in any group. The frequency of digestive symptoms was not different between scFOS at any of the doses tested and placebo. Bloating was significantly more intense during scFOS ingestion at doses of 2.5 and 5 g/d, but not at doses of 7.5 and 10 g/d. Excess flatus, borborygmi and abdominal pain did not differ from the placebo at any of the doses tested. This study showed that scFOS is bifidogenic and well tolerated at doses ranging from 2.5 to 10 g/d, and that there is a dose-response relationship in healthy volunteers. |
| ArticleNumber | 8 |
| Author | Bouhnik, Yoram Paineau, Damien Simoneau, Guy Bornet, Francis Raskine, Laurent |
| AuthorAffiliation | 3 Unité de Recherche Thérapeutique, Hôpital Lariboisière, 2 rue Ambroise Paré, 75475 Paris Cedex 10, France 1 Hépato-Gastroentérologie et Assistance Nutritive, Hôpital Lariboisière, 2 rue Ambroise Paré, 75475 Paris Cedex 10, France 4 Nutri-Health SA, 3 avenue Paul Doumer, 92500 Rueil-Malmaison, France 2 Bactériologie – Virologie, Hôpital Lariboisière, 2 rue Ambroise Paré, 75475 Paris Cedex 10, France |
| AuthorAffiliation_xml | – name: 2 Bactériologie – Virologie, Hôpital Lariboisière, 2 rue Ambroise Paré, 75475 Paris Cedex 10, France – name: 3 Unité de Recherche Thérapeutique, Hôpital Lariboisière, 2 rue Ambroise Paré, 75475 Paris Cedex 10, France – name: 1 Hépato-Gastroentérologie et Assistance Nutritive, Hôpital Lariboisière, 2 rue Ambroise Paré, 75475 Paris Cedex 10, France – name: 4 Nutri-Health SA, 3 avenue Paul Doumer, 92500 Rueil-Malmaison, France |
| Author_xml | – sequence: 1 givenname: Yoram surname: Bouhnik fullname: Bouhnik, Yoram – sequence: 2 givenname: Laurent surname: Raskine fullname: Raskine, Laurent – sequence: 3 givenname: Guy surname: Simoneau fullname: Simoneau, Guy – sequence: 4 givenname: Damien surname: Paineau fullname: Paineau, Damien – sequence: 5 givenname: Francis surname: Bornet fullname: Bornet, Francis |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/16569219$$D View this record in MEDLINE/PubMed |
| BookMark | eNqFkk1v1DAQhiNURD_gyBX5xC0QO3Fic0Cgio9KlbiUszWxxxtXSRxsp9L-B3403m4pXVDFyeOZ149nNO9pcTT7GYviJa3eUCrat7TpeMmEpCUvxZPi5P5-9CA-Lk5jvK4qJoTsnhXHtOWtZFSeFD-vBiQaFtAubYm3JA4-pFIP4GZiw6qTL_3oNj6CzsngDEaSPInJTesICYkF1DCS3llnfA86YXDwjgAxPmIZMC5-jkgCZrXL4eCW_Ho1W5J_GBDGNGzJsE4wx-fFUwtjxBd351nx_fOnq_Ov5eW3LxfnHy_LntcylVbLzlJupGg5Z12PDZXWAKslY5S3FESe2zAuQHe6Z5SJ2nY9Z0JL3dLe1mfFxZ5rPFyrJbgJwlZ5cOo24cNGQUhOj6h4LwRrRF2D4A0aCRZMS7ls2k6YBllmvd-zlrWf0GicU4DxAHpYmd2gNv5G0aYRVFYZ8GEP6J1_BHBY0X5Su82q3WYVVyIjXt_1EPyPFWNSk4saxxFm9GtUbSerVlbyv0Iqs0M63mbhq4dT3Xfz2zhZUO4FOvgYA9o_kkrtjPlPi_Vf-my4W0Pkmdz4yKtfU3zp0w |
| CitedBy_id | crossref_primary_10_2903_j_efsa_2011_2023 crossref_primary_10_3945_jn_112_173096 crossref_primary_10_3390_nu14071461 crossref_primary_10_1007_s13353_021_00624_5 crossref_primary_10_1016_j_heliyon_2021_e06805 crossref_primary_10_1186_1475_2891_6_42 crossref_primary_10_1093_advances_nmab119 crossref_primary_10_2903_j_efsa_2011_2222 crossref_primary_10_1016_j_appet_2010_12_005 crossref_primary_10_1017_S0007114517002318 crossref_primary_10_29254_2077_4214_2017_4_3_141_52_57 crossref_primary_10_1016_j_procbio_2023_12_015 crossref_primary_10_3390_nu9020125 crossref_primary_10_1155_2018_7497260 crossref_primary_10_1177_0884533613503555 crossref_primary_10_2903_j_efsa_2016_4366 crossref_primary_10_1038_s41598_019_41837_3 crossref_primary_10_3390_nu14163298 crossref_primary_10_1093_nutrit_nuab115 crossref_primary_10_1007_s12010_019_03215_7 crossref_primary_10_1093_ajcn_nqy041 crossref_primary_10_1016_j_ekir_2023_12_017 crossref_primary_10_18178_ijfe_4_4_322_326 crossref_primary_10_2903_j_efsa_2010_1809 crossref_primary_10_1080_10408398_2022_2154744 crossref_primary_10_1616_1476_2137_15989 crossref_primary_10_3390_nu12071999 crossref_primary_10_1616_1476_2137_15746 crossref_primary_10_1002_jsfa_11884 crossref_primary_10_1017_S0007114514000075 crossref_primary_10_1111_jam_15319 crossref_primary_10_1038_ejcn_2009_64 crossref_primary_10_3747_pdi_2014_00015 crossref_primary_10_31146_1682_8658_ecg_220_12_4_18 crossref_primary_10_1080_1745039X_2010_504607 crossref_primary_10_3389_fimmu_2020_600125 crossref_primary_10_3389_fmicb_2017_01265 crossref_primary_10_1080_10408398_2024_2397459 crossref_primary_10_3390_nu12041037 crossref_primary_10_1146_annurev_food_080708_100746 crossref_primary_10_1038_ctg_2016_22 crossref_primary_10_3390_diagnostics11061090 crossref_primary_10_1016_j_clnesp_2023_04_014 crossref_primary_10_3390_microorganisms10122507 crossref_primary_10_1136_bmjopen_2021_049184 crossref_primary_10_1590_s0004_2803_201700000_07 crossref_primary_10_1016_j_jff_2024_106356 crossref_primary_10_1016_j_jfca_2021_103884 crossref_primary_10_1017_S0007114516000908 crossref_primary_10_3390_foods9101500 crossref_primary_10_1016_j_ijfoodmicro_2009_08_004 crossref_primary_10_1007_s00203_010_0628_y crossref_primary_10_3892_ijmm_2017_3072 crossref_primary_10_1016_j_jfca_2010_12_001 crossref_primary_10_1017_jns_2014_52 crossref_primary_10_1017_S0007114510001571 crossref_primary_10_1016_j_bpg_2007_03_007 crossref_primary_10_1371_journal_pone_0017315 crossref_primary_10_1021_pr060265y crossref_primary_10_1080_10408398_2012_656772 crossref_primary_10_1155_2012_493717 crossref_primary_10_1016_j_anifeedsci_2010_03_001 crossref_primary_10_3390_microorganisms10122338 crossref_primary_10_1093_nutrit_nuae002 crossref_primary_10_3177_jnsv_60_167 crossref_primary_10_1007_s10620_006_9652_9 crossref_primary_10_1016_j_clnu_2021_05_033 crossref_primary_10_1016_j_jff_2018_10_035 crossref_primary_10_1186_s40168_021_01061_6 crossref_primary_10_1016_j_jff_2015_05_004 crossref_primary_10_1017_S000711450779894X crossref_primary_10_3390_microorganisms9081634 crossref_primary_10_1038_ejcn_2014_30 crossref_primary_10_1186_s40168_018_0494_4 crossref_primary_10_1016_j_tifs_2016_08_015 crossref_primary_10_1111_nmo_12911 crossref_primary_10_1186_1475_2891_12_127 crossref_primary_10_1016_j_jbiotec_2011_07_026 crossref_primary_10_1021_jf505156h crossref_primary_10_3390_nu9030196 crossref_primary_10_1016_j_anifeedsci_2010_09_006 crossref_primary_10_3389_fnut_2018_00080 crossref_primary_10_1016_j_jff_2014_10_029 crossref_primary_10_1038_ismej_2014_63 crossref_primary_10_1017_S000711451000036X crossref_primary_10_3390_nu12103035 |
| Cites_doi | 10.1093/ajcn/64.3.324 10.1002/food.19870310528 10.1093/jn/129.1.113 10.1177/014107688207500907 10.1093/ajcn/63.5.709 10.1093/jn/125.6.1401 10.1093/ajcn/52.4.675 10.1136/bmj.3.5770.338 10.1177/014107688507800311 10.12938/bifidus1982.5.1_37 10.1093/jn/128.1.11 10.1136/gut.29.8.1035 10.1093/ajcn/46.1.61 10.1080/01635589609514459 10.1097/00005176-200203000-00014 10.1016/0016-5085(95)90192-2 10.1172/JCI111738 10.1093/ajcn/80.6.1658 10.1093/jn/129.7.1442S |
| ContentType | Journal Article |
| Copyright | Copyright © 2006 Bouhnik et al; licensee BioMed Central Ltd. 2006 Bouhnik et al; licensee BioMed Central Ltd. |
| Copyright_xml | – notice: Copyright © 2006 Bouhnik et al; licensee BioMed Central Ltd. 2006 Bouhnik et al; licensee BioMed Central Ltd. |
| DBID | AAYXX CITATION CGR CUY CVF ECM EIF NPM 7QL C1K 7X8 5PM DOA |
| DOI | 10.1186/1475-2891-5-8 |
| DatabaseName | CrossRef Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed Bacteriology Abstracts (Microbiology B) Environmental Sciences and Pollution Management MEDLINE - Academic PubMed Central (Full Participant titles) DOAJ Directory of Open Access Journals |
| DatabaseTitle | CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) Bacteriology Abstracts (Microbiology B) Environmental Sciences and Pollution Management MEDLINE - Academic |
| DatabaseTitleList | MEDLINE - Academic Bacteriology Abstracts (Microbiology B) MEDLINE |
| Database_xml | – sequence: 1 dbid: DOA name: Directory of Open Access Journals (DOAJ) url: https://www.doaj.org/ sourceTypes: Open Website – sequence: 2 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 3 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Anatomy & Physiology Diet & Clinical Nutrition |
| EISSN | 1475-2891 |
| EndPage | 8 |
| ExternalDocumentID | oai_doaj_org_article_5b8824833a854ed9afad61594678d4e2 PMC1448190 oai_biomedcentral_com_1475_2891_5_8 16569219 10_1186_1475_2891_5_8 |
| Genre | Randomized Controlled Trial Research Support, Non-U.S. Gov't Journal Article |
| GroupedDBID | --- 0R~ 123 29N 2VQ 2WC 4.4 53G 5VS A8Z AAFWJ AAHBH AAJSJ AASML AAWTL AAYXX ABDBF ACGFO ACGFS ACIHN ACPRK ACUHS ADBBV ADRAZ ADUKV AEAQA AENEX AFPKN AHBYD AHMBA AHSBF AHYZX ALIPV ALMA_UNASSIGNED_HOLDINGS AMKLP AMTXH AOIJS BAPOH BAWUL BCNDV BFQNJ BMC C1A C6C CITATION CS3 DIK DU5 E3Z EAD EAP EAS EBLON EBS ECGQY EJD EMB EMK EMOBN ESTFP ESX F5P GROUPED_DOAJ GX1 H13 HH5 HYE IAO ICU IHR IHT INH INR IPNFZ ISE KQ8 M48 M~E O5R O5S OK1 OVT P2P PGMZT QF4 QN7 RBZ RIG RNS ROL RPM RSV SCM SOJ SV3 TR2 TUS W2D WOQ WOW XSB -A0 ACRMQ ADINQ C24 CGR CUY CVF ECM EIF FRP NPM 7QL C1K 7X8 ABVAZ AFGXO AFNRJ 5PM |
| ID | FETCH-LOGICAL-b539t-fc97f15d9865527be419fda239221561a8475d258ac7cb21283f7b528c9c61bf3 |
| IEDL.DBID | RBZ |
| ISSN | 1475-2891 |
| IngestDate | Wed Aug 27 01:00:29 EDT 2025 Thu Aug 21 18:17:29 EDT 2025 Wed May 22 07:13:13 EDT 2024 Fri Jul 11 15:45:47 EDT 2025 Thu Jul 10 21:57:10 EDT 2025 Thu Jan 02 22:01:52 EST 2025 Tue Jul 01 03:09:30 EDT 2025 Thu Apr 24 23:12:14 EDT 2025 |
| IsDoiOpenAccess | true |
| IsOpenAccess | true |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 1 |
| Language | English |
| License | This is an Open Access article distributed under the terms of the Creative Commons Attribution License (), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-b539t-fc97f15d9865527be419fda239221561a8475d258ac7cb21283f7b528c9c61bf3 |
| Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 ObjectType-Undefined-3 |
| OpenAccessLink | http://dx.doi.org/10.1186/1475-2891-5-8 |
| PMID | 16569219 |
| PQID | 19288756 |
| PQPubID | 23462 |
| PageCount | 1 |
| ParticipantIDs | doaj_primary_oai_doaj_org_article_5b8824833a854ed9afad61594678d4e2 pubmedcentral_primary_oai_pubmedcentral_nih_gov_1448190 biomedcentral_primary_oai_biomedcentral_com_1475_2891_5_8 proquest_miscellaneous_67906909 proquest_miscellaneous_19288756 pubmed_primary_16569219 crossref_primary_10_1186_1475_2891_5_8 crossref_citationtrail_10_1186_1475_2891_5_8 |
| ProviderPackageCode | CITATION AAYXX |
| PublicationCentury | 2000 |
| PublicationDate | 2006-03-28 |
| PublicationDateYYYYMMDD | 2006-03-28 |
| PublicationDate_xml | – month: 03 year: 2006 text: 2006-03-28 day: 28 |
| PublicationDecade | 2000 |
| PublicationPlace | England |
| PublicationPlace_xml | – name: England – name: London |
| PublicationTitle | Nutrition journal |
| PublicationTitleAlternate | Nutr J |
| PublicationYear | 2006 |
| Publisher | BioMed Central Ltd BioMed Central BMC |
| Publisher_xml | – name: BioMed Central Ltd – name: BioMed Central – name: BMC |
| References | SL Malhotra (92_CR14) 1982; 75 MB Roberfroid (92_CR10) 1998; 128 H Hidaka (92_CR15) 1986; 5 T Stone-Dorshow (92_CR21) 1987; 46 T Mitsuoka (92_CR12) 1987; 31 DF Evans (92_CR16) 1988; 29 C Molis (92_CR2) 1996; 64 JJ Rumessen (92_CR19) 1990; 52 GR Gibson (92_CR18) 1995; 108 AV Rao (92_CR9) 1999; 129 M Hirayama (92_CR1) 1989; 53 RK Buddington (92_CR4) 1996; 63 Y Bouhnik (92_CR8) 1999; 129 Y Bouhnik (92_CR5) 1996; 26 G Moro (92_CR11) 2002; 34 SL Samelson (92_CR13) 1985; 78 C Florent (92_CR17) 1985; 75 CL Bullen (92_CR6) 1971; 3 F Briet (92_CR20) 1995; 49 Y Bouhnik (92_CR7) 2004; 6 GR Gibson (92_CR3) 1995; 125 2206038 - Am J Clin Nutr. 1990 Oct;52(4):675-81 7698613 - Gastroenterology. 1995 Apr;108(4):975-82 8615353 - Am J Clin Nutr. 1996 May;63(5):709-16 9430596 - J Nutr. 1998 Jan;128(1):11-9 3973020 - J Clin Invest. 1985 Feb;75(2):608-13 3973888 - J R Soc Med. 1985 Mar;78(3):230-3 3410329 - Gut. 1988 Aug;29(8):1035-41 7588500 - Eur J Clin Nutr. 1995 Jul;49(7):501-7 8780341 - Am J Clin Nutr. 1996 Sep;64(3):324-8 8844718 - Nutr Cancer. 1996;26(1):21-9 10395617 - J Nutr. 1999 Jul;129(7 Suppl):1442S-5S 3604970 - Am J Clin Nutr. 1987 Jul;46(1):61-5 4934188 - Br Med J. 1971 Aug 7;3(5770):338-43 11964956 - J Pediatr Gastroenterol Nutr. 2002 Mar;34(3):291-5 7782892 - J Nutr. 1995 Jun;125(6):1401-12 15585783 - Am J Clin Nutr. 2004 Dec;80(6):1658-64 7120255 - J R Soc Med. 1982 Sep;75(9):709-14 3657917 - Nahrung. 1987;31(5-6):427-36 9915885 - J Nutr. 1999 Jan;129(1):113-6 |
| References_xml | – volume: 64 start-page: 324 year: 1996 ident: 92_CR2 publication-title: Am J Clin Nutr doi: 10.1093/ajcn/64.3.324 – volume: 31 start-page: 427 year: 1987 ident: 92_CR12 publication-title: Nahrung doi: 10.1002/food.19870310528 – volume: 129 start-page: 113 year: 1999 ident: 92_CR8 publication-title: J Nutr doi: 10.1093/jn/129.1.113 – volume: 75 start-page: 709 year: 1982 ident: 92_CR14 publication-title: J R Soc Med doi: 10.1177/014107688207500907 – volume: 63 start-page: 709 year: 1996 ident: 92_CR4 publication-title: Am J Clin Nutr doi: 10.1093/ajcn/63.5.709 – volume: 125 start-page: 1401 year: 1995 ident: 92_CR3 publication-title: J Nutr doi: 10.1093/jn/125.6.1401 – volume: 52 start-page: 675 year: 1990 ident: 92_CR19 publication-title: Am J Clin Nutr doi: 10.1093/ajcn/52.4.675 – volume: 49 start-page: 501 year: 1995 ident: 92_CR20 publication-title: Eur J Clin Nutr – volume: 3 start-page: 338 year: 1971 ident: 92_CR6 publication-title: Br Med J doi: 10.1136/bmj.3.5770.338 – volume: 53 start-page: 667 year: 1989 ident: 92_CR1 publication-title: Agric Biol Chem – volume: 78 start-page: 230 year: 1985 ident: 92_CR13 publication-title: J R Soc Med doi: 10.1177/014107688507800311 – volume: 5 start-page: 37 year: 1986 ident: 92_CR15 publication-title: Bifidobacteria Microflora doi: 10.12938/bifidus1982.5.1_37 – volume: 128 start-page: 11 year: 1998 ident: 92_CR10 publication-title: J Nutr doi: 10.1093/jn/128.1.11 – volume: 29 start-page: 1035 year: 1988 ident: 92_CR16 publication-title: Gut doi: 10.1136/gut.29.8.1035 – volume: 46 start-page: 61 year: 1987 ident: 92_CR21 publication-title: Am J Clin Nutr doi: 10.1093/ajcn/46.1.61 – volume: 26 start-page: 21 year: 1996 ident: 92_CR5 publication-title: Nutr Cancer doi: 10.1080/01635589609514459 – volume: 34 start-page: 291 year: 2002 ident: 92_CR11 publication-title: J Pediatr Gastroenterol Nutr doi: 10.1097/00005176-200203000-00014 – volume: 108 start-page: 975 year: 1995 ident: 92_CR18 publication-title: Gastroenterology doi: 10.1016/0016-5085(95)90192-2 – volume: 75 start-page: 608 year: 1985 ident: 92_CR17 publication-title: J Clin Invest doi: 10.1172/JCI111738 – volume: 6 start-page: 1658 year: 2004 ident: 92_CR7 publication-title: Am J Clin Nutr doi: 10.1093/ajcn/80.6.1658 – volume: 129 start-page: 1442S year: 1999 ident: 92_CR9 publication-title: J Nutr doi: 10.1093/jn/129.7.1442S – reference: 3973888 - J R Soc Med. 1985 Mar;78(3):230-3 – reference: 7698613 - Gastroenterology. 1995 Apr;108(4):975-82 – reference: 3657917 - Nahrung. 1987;31(5-6):427-36 – reference: 7588500 - Eur J Clin Nutr. 1995 Jul;49(7):501-7 – reference: 8615353 - Am J Clin Nutr. 1996 May;63(5):709-16 – reference: 11964956 - J Pediatr Gastroenterol Nutr. 2002 Mar;34(3):291-5 – reference: 4934188 - Br Med J. 1971 Aug 7;3(5770):338-43 – reference: 7120255 - J R Soc Med. 1982 Sep;75(9):709-14 – reference: 3410329 - Gut. 1988 Aug;29(8):1035-41 – reference: 8780341 - Am J Clin Nutr. 1996 Sep;64(3):324-8 – reference: 8844718 - Nutr Cancer. 1996;26(1):21-9 – reference: 2206038 - Am J Clin Nutr. 1990 Oct;52(4):675-81 – reference: 9915885 - J Nutr. 1999 Jan;129(1):113-6 – reference: 10395617 - J Nutr. 1999 Jul;129(7 Suppl):1442S-5S – reference: 3973020 - J Clin Invest. 1985 Feb;75(2):608-13 – reference: 15585783 - Am J Clin Nutr. 2004 Dec;80(6):1658-64 – reference: 7782892 - J Nutr. 1995 Jun;125(6):1401-12 – reference: 9430596 - J Nutr. 1998 Jan;128(1):11-9 – reference: 3604970 - Am J Clin Nutr. 1987 Jul;46(1):61-5 |
| SSID | ssj0028897 |
| Score | 2.1185284 |
| Snippet | Short-chain fructo-oligosaccharides (scFOS) are well-known for their bifidogenicity. In a large study comprising 200 healthy volunteers, we determined the... Background Short-chain fructo-oligosaccharides (scFOS) are well-known for their bifidogenicity. In a large study comprising 200 healthy volunteers, we... BACKGROUND: Short-chain fructo-oligosaccharides (scFOS) are well-known for their bifidogenicity. In a large study comprising 200 healthy volunteers, we... Abstract Background Short-chain fructo-oligosaccharides (scFOS) are well-known for their bifidogenicity. In a large study comprising 200 healthy volunteers, we... |
| SourceID | doaj pubmedcentral biomedcentral proquest pubmed crossref |
| SourceType | Open Website Open Access Repository Aggregation Database Index Database Enrichment Source |
| StartPage | 8 |
| SubjectTerms | Bacteroides Bifidobacterium - drug effects Colony Count, Microbial Diet Feces - microbiology Female Humans Lactobacillus Male Oligosaccharides - administration & dosage Oligosaccharides - adverse effects Placebos |
| SummonAdditionalLinks | – databaseName: DOAJ Directory of Open Access Journals dbid: DOA link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV3LbtwgFEVVVt1UbdKH-2RRZVWUwQYbuksfUVSpWTVSdohnx9LEjsbOIv_Qj-4F7DQeNeqmW8AGmwvnXPtyLkLvabNytVgFwqizhAlTElNrTpzVhlIHHoONjuL3s_r0nH274Bd3Un3FmLAsD5xf3BE3wAGZqCotOPNO6qAdoHDMDC8c82n3BcybnanJ1RIip1VhDSfgUtBZXVPUR7dlhBOxc8x9s0CnJOL_N-a5G0B5B5FOHqNHE5XEx_kRnqAHvttHB8cduNGXN_gQp-DO9NV8HxVfWj9C2SQDusFnswr_AfoFpoItgKYFRo77gIc1cHJi17rtcIjysj3pN-3PftA2HtJqnR_w2GPYHC5j8i-Pg_bxnqYNrYP9Iek_649YY9cPnmxzGK7H2znwbt1e4aRri6GHfBLzBqdsgcNTdH7y9cfnUzIlaSCGV3IkwcomUO5kPOFaNsYzKoPTJfAuYBM11QB_3JVcaNtYA0ApqtAYXgorbU1NqJ6hva7v_AuEV4Y7XXmuhXdMcC-Fh6ujHn6kjaYpkFxMlrrKghwqSmQva2C1qjjRKk604koU6MM8scpO6ucxCcdGJS9I1LvND2-bz73c0_BTtJLFUFIB2LCabFj9y4YL9G62MQWrO_6y0Z3vrwcF_BtQgNf3t6gbGcWmZYGeZ5v8M16g6hIAqUDNwloXY13WdO06KYyDlx2Z4sv_8XCv0MP82aqCVfca7Y3ba_8GiNxo3qY1-xsDGUiv priority: 102 providerName: Directory of Open Access Journals – databaseName: Scholars Portal Journals: Open Access dbid: M48 link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV1Lb9QwELagXLggaHmEpw-oJwybxE5sJITKo6qQ2hMr9Wb52Y2UJiXZSux_4EczdpKWrNoT12SSWPaMv28c-xuE3qblwhZ84QlNrSGU64zoQjFijdJpaiFjMCFRPD4pjpb0xyk7vZYUGjuwvzG1C_Wkll39_vevzWcI-E8x4HnxIaUlI5A4pIQRfhfdA1AqQxWHY3r1QyHjfKizMplOcpvbj2-de69ncBVV_W-iots7Kv-BqMOH6MHILfHB4AyP0B3X7KK9gwby6vMN3sdxt2dcRt9FybfKreHaqAta45NJln8P_QHfwQZQ1ABFx63H_Qr6h5iVqhrsg95sS9q6Omt7ZcKprcq6Hq9bDLPFeagG5rBXLrxTV76yMGFEQWj1ESts296RbtiX63A37cRbVRc4Ct1i-MJwNHODY_nA_jFaHn7_-fWIjFUbiGa5WBNvROlTZkU48pqV2tFUeKsyIGJAL4pUAR4ymzGuTGk0ICfPfalZxo0wRap9_gTtNG3jniG80Myq3DHFnaWcOcEdPB0E8gOP1GWCxGyw5MWg0CGDZvb8DoSvDAMtw0BLJnmC3k0DK80ohx6qctQypkW82DbfvzKfvnKL4ZfgJbOmxAttdybH2UAyDYkN5XmuOKPOCuWVBWopALW4pS5L0JvJxySEe_iHoxrXXvYSCDnAAitutyhKEdSnRYKeDj553V7g7gIQKkHlzFtnbZ3faapVlByHtDtQx-f_0eEv0P1h-SqHYHuJdtbdpXsFhG6tX8dQ_QvDC049 priority: 102 providerName: Scholars Portal |
| Title | The capacity of short-chain fructo-oligosaccharides to stimulate faecal bifidobacteria: a dose-response relationship study in healthy humans |
| URI | https://www.ncbi.nlm.nih.gov/pubmed/16569219 https://www.proquest.com/docview/19288756 https://www.proquest.com/docview/67906909 http://dx.doi.org/10.1186/1475-2891-5-8 https://pubmed.ncbi.nlm.nih.gov/PMC1448190 https://doaj.org/article/5b8824833a854ed9afad61594678d4e2 |
| Volume | 5 |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV1Lb9QwELagvXBB0PIIj8UH1BMW68RO7N62QFWt1B6AShUXy0820japNttD_wM_umNn05IVPXHJwZkkVmbG840f3yD0kVZTV4ppIIw6S5gwOTGl5sRZbSh1kDHYmCienpUn52x-wS_uSZK2VvCpKD9TVnECaQElnIjHaDdnFYs1Gr4f_brLrIToq6gMogOZ5vbjW6fal6NglDj7_wU0t_dL_hWAjp-hpxvkiGe9qp-jR77ZQ_uzBrLmyxt8gNNezjRJvoeyr7VfQ9uG9XOJzwbS_X30BywDW4iRFgA4bgPuFgDBiV3ousEhssm2pF3Wv9tO23gmq3a-w-sWw1hwGWt9eRy0j-80dagdDAeJ7lkfYo1d23my6nfderwa9tkt6iucaGwxfKE_eHmDU3HA7gU6P_7288sJ2dRkIIYXck2ClVWg3Ml4oDWvjGdUBqdzgFkAHkqqIdpxl3OhbWUNxEVRhMrwXFhpS2pC8RLtNG3jXyM8NdzpwnMtvGOCeyk8PB3p7yNKNFWG5EhZ6qrn31CREXt8B5xTRUWrqGjFlcjQp0Gxym7IzmPNjaVKSY8ot8UP7sSHrzwgeBStZNSV1AAWqza-rriBtIWJotCCM--kDtoBcJQQk4RjPs_Qh8HGFDhzXKHRjW-vOwVwGwZ9Xj4sUVYyckvLDL3qbfK-v4DMJcSfDFUjax31dXynqReJUByS6ggM3_zHD3-LnvSTUwU42zu0s15d-_cA19ZmgnZns_mP-SRNd8D1lIlJct9b_u9ECw |
| linkProvider | BioMedCentral |
| linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV1Lb9QwELagHOCCSgs0FKgPqCcMm4djm1sLVAu0e0CtVHGx_OxG2ibVZnvof-BHM3aS0qzoiWsySSx7xvONM_MNQu9SNrEln3hSpNaQguuM6FJRYo3SaWohYjAhUDyZldOz4vs5Pe8phUItTD1w0PdT-eFuFfoibt1Dxlhn8Lz8mBaMEggcUkIJf4geMUpZsNGfh79uYy_Ouz4rg-hAt7n--Frd-2LkriKr_7-g6HpG5R0XdbSJnvbYEh90I3-GHrh6C20f1BBXX97gfRyzPeMx-hZKvlRuBdd6XtAFng1Tso1-g-5gA17UAETHjcftHEA6MXNV1dgHvtmGNIvqommVCVVblXUtXjUYdovL0A3MYa9ceKeufGVhw4iE0OoTVtg2rSPLLi_X4eWQiTevrnAkusXwha408wbH9oHtc3R29PX085T0XRuIprlYEW8E8ym1IpS8Zky7IhXeqgyAGMCLMlXgD6nNKFeGGQ2ek-eeaZpxI0yZap-_QBt1U7sdhCeaWpU7qrizBadOcAdPB4L8gCM1S5AYLZa86hg6ZODMHt8BxZFhoWVYaEklT9D7YWGl6enQQ1eOhYxhES_XxfdvxYev3CN4GLRkNJR4oVleyF51JdUQ2BQ8zxWnhbNCeWUBWgrwWtwWLkvQ3qBjEsw9_MNRtWuuWwmAHNwCLe-XKJkI7NMiQS87nfw7XsDuAjxUgthIW0djHd-pq3mkHIewO0DHV_8x4Xvo8fT05Fgef5v92EVPuqOsHAzvNdpYLa_dGwB3K_02mu0fgBlR3A |
| linkToPdf | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV1Lb9QwELagSIgLghZoeNUH1BOmm4cTm1tLWZXXigOVKi6Wn92INFlt0kP_Az-asZOUZkVP3CJnklj22PONM_MNQm_iYmZyNnMki40mGVMJUbmkxGip4tiAx6C9o_htkZ-cZp_P6NkQ_-RzYeqRg34Yync3s9CrsHXDhf51sDKuX_EsP4izghLwHGJCCbuL7hWeV8p77kc_r50vxvpCK6PoyLe5-fhG4ns1sVeB1v9fWHQzpPKGjZo_Qg8HcIkPe214jO7YehvtHNbgWF9c4X0cwj3DOfo2io5L20HbQAxa4cU4JjvoNygP1mBGNWB03DjcLgGlE72UZY2dJ5xtSFOV500rtU_bKo1tcddg2C4ufDkwi520_p2qdKWBHSMwQsv3WGLTtJas-8Bci9djKN6yXOHAdIvhC31u5hUO9QPbJ-h0_vHHhxMylG0giqa8I07zwsXUcJ_zmhTKZjF3RiaAxABf5LEEg0hNQpnUhVZgOlnqCkUTprnOY-XSp2irbmq7i_BMUSNTSyWzJmPUcmbhac-Q74GkKiLEJ5MlVj1Fh_Ck2dM7oDnCT7TwEy2oYBF6O06s0AMfui_LUYngF7F8U3z_Wnz8yi2CR15LJl0JDc36XAzbgaAKPJuMpalkNLOGSycNYEsOZouZzCYR2ht1TMB69z9xZG2by1YAIge7QPPbJfKCe_ppHqFnvU7-7S-Adw4mKkLFRFsnfZ3eqctl4BwHv9tjx-f_MeB76P7347n4-mnx5QV60B9lpbDuXqKtbn1pXwG469TrsGr_AOAGUac |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=The+capacity+of+short-chain+fructo-oligosaccharides+to+stimulate+faecal+bifidobacteria%3A+a+dose-response+relationship+study+in+healthy+humans&rft.jtitle=Nutrition+journal&rft.au=Bouhnik%2C+Yoram&rft.au=Raskine%2C+Laurent&rft.au=Simoneau%2C+Guy&rft.au=Paineau%2C+Damien&rft.date=2006-03-28&rft.pub=BioMed+Central+Ltd&rft.issn=1475-2891&rft.eissn=1475-2891&rft.volume=5&rft.issue=1&rft.spage=8&rft.epage=8&rft_id=info:doi/10.1186%2F1475-2891-5-8&rft.externalDBID=n%2Fa&rft.externalDocID=oai_biomedcentral_com_1475_2891_5_8 |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1475-2891&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1475-2891&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1475-2891&client=summon |